Sheetal Kircher, MD
Medical Oncology · Chicago, ILNPI 1215184577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $4,251 with a category attached, or 70.6%. Pfizer accounts for 95.2% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $4,098 and has fallen 98.3% since, to $68 in 2025.
Across 6 payments — averaging $708.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- AstraZeneca$202
Across 11 payments — averaging $6921.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$76K
What the payments were for
- Speaking & faculty fees$3,00071%
- Travel & lodging$92922%
- Food & beverage$2546%
- Education$682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $4,049 |
| AstraZeneca | 3 | $202 |
How this compares
$4,251 in reported general payments places this provider in the 65th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 23 | $65,787 |
| ZenpepLipase/Protease/Amylase | 14 | $58,669 |
| Gabapentin | 22 | $446 |
| LoperamideLoperamide Hcl | 13 | $348 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $197 |
| Amlodipine Besylate | 11 | $7 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Chicago
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Jyoti PatelChicago$175K
- Al BensonChicago$163K
- Nisha MohindraChicago$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.